Eisai Opts In On Biogen's High-Profile Aducanumab
Biogen secures stronger economics for the Phase III Alzheimer's disease drug in the US and Europe in the joint development/commercialization agreement; Eisai picked up rights to Biogen's MS portfolio in Japan and other Asian markets.
You may also be interested in...
In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.
Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.
Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.